{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05891613",
            "orgStudyIdInfo": {
                "id": "21-007358"
            },
            "organization": {
                "fullName": "Mayo Clinic",
                "class": "OTHER"
            },
            "briefTitle": "A Study of Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride Post Breast Reduction",
            "officialTitle": "Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride for Postoperative Analgesia After Breast Reduction Surgery: A Prospective, Single Blind, Non-randomized Controlled Trial",
            "therapeuticArea": [
                "Women's Health"
            ],
            "study": "a-study-of-liposomal-bupivacaine-versus-bupivacaine-hydrochloride-post-breast-reduction"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-01-24",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-05-26",
            "studyFirstSubmitQcDate": "2023-05-26",
            "studyFirstPostDateStruct": {
                "date": "2023-06-07",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-15",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-17",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Basel A. Sharaf",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "Mayo Clinic"
            },
            "leadSponsor": {
                "name": "Mayo Clinic",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this research is to assess pain scores and opioid use when using Liposomal (Exparel) Bupivacaine versus Bupivacaine Hydrochloride.",
            "detailedDescription": "This is a prospective, multi-surgeon, single blind, non-randomized, controlled trial with breasts allocated to two parallel groups: A mixture of liposomal (Exparel) bupivacaine with plain 0.25% bupivacaine hydrochloride will be used on one side (Treatment side) as local infiltration, and plain 0.25% Bupivacaine Hydrochloride will be used in the control arm. Each breast will serve as the control for the other. The study is designed to evaluate early postoperative pain control of each of the products up to 72 hours postoperatively. These treatments are standard of care in clinical practice."
        },
        "conditionsModule": {
            "conditions": [
                "Breast Reduction"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "SINGLE",
                    "whoMasked": [
                        "PARTICIPANT"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 42,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Control Breast Treatment Group: Bupivacaine Hydrochloride",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Subjects undergoing breast reduction surgery will receive standard 0.25% Bupivacaine Hydrochloride in one breast.",
                    "interventionNames": [
                        "Drug: Bupivacaine Hydrochloride"
                    ]
                },
                {
                    "label": "Treatment Breast Treatment Group: Liposomal (Exparel) Bupivacaine",
                    "type": "EXPERIMENTAL",
                    "description": "Subjects undergoing breast reduction surgery will receive a mixture of liposomal (Exparel) bupivacaine with plain 0.25% bupivacaine hydrochloride in contralateral breast.",
                    "interventionNames": [
                        "Drug: Bupivacaine Hydrochloride",
                        "Drug: Liposomal Bupivacaine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Bupivacaine Hydrochloride",
                    "description": "20 ml of 0.25% Bupivacaine (50 mg) with 20 ml of injectable saline (total of 40 cc) as a subcutaneous infiltration along the inframammary fold incision on one breast",
                    "armGroupLabels": [
                        "Control Breast Treatment Group: Bupivacaine Hydrochloride",
                        "Treatment Breast Treatment Group: Liposomal (Exparel) Bupivacaine"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Liposomal Bupivacaine",
                    "description": "20 ml of Liposomal (Exparel) Bupivacaine (266 mg/20 ml) on the contralateral breast",
                    "armGroupLabels": [
                        "Treatment Breast Treatment Group: Liposomal (Exparel) Bupivacaine"
                    ],
                    "otherNames": [
                        "Exparel"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Pain Scores in the first 72 hours post-operatively following breast reduction",
                    "description": "Measured using validated self-reported Numerical Pain Rating Scale (NPRS). Participants rate pain using a scale of 0=none and 10=most severe.",
                    "timeFrame": "72 hours post-operatively"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria\n\n- Adult female patients (18-70 years old) with symptomatic macromastia scheduled for breast reduction using a Wise pattern incision design.\n\nExclusion Criteria\n\n* Inability to provide informed consent\n* Medical or surgical history precluding breast reduction\n* History of significant chronic pain requiring daily use of opioid or nonopioid analgesics\n* Pregnancy\n* Concomitant non-breast surgical procedure\n* Previous chest wall irradiation\n* Previous breast implant, breast reduction or breast lift surgery\n* Known allergy to bupivacaine or liposomal bupivacaine\n* Liver or kidney dysfunction\n* Use of antiplatelet or anticoagulation therapy.",
            "healthyVolunteers": true,
            "sex": "FEMALE",
            "minimumAge": "18 Years",
            "maximumAge": "70 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "BMSO Research Team",
                    "role": "CONTACT",
                    "phone": "507-538-4849",
                    "email": "BMSORESEARCH@mayo.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Basel Sharaf, MD, DDS",
                    "affiliation": "Mayo Clinic",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Mayo Clinic Minnesota",
                    "status": "RECRUITING",
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55905",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "BMSO Research Group",
                            "role": "CONTACT",
                            "phone": "507-538-4849",
                            "email": "BMSORESEARCH@mayo.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.02163,
                        "lon": -92.4699
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002045",
                    "term": "Bupivacaine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000779",
                    "term": "Anesthetics, Local"
                },
                {
                    "id": "D000000777",
                    "term": "Anesthetics"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5315",
                    "name": "Bupivacaine",
                    "asFound": "Type",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4107",
                    "name": "Anesthetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M4109",
                    "name": "Anesthetics, Local",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}